

Internationally renowned healthcare executive, Mr Herwig Janssen appointed as Chairman

- Mr Janssen is a global leader in the pharmaceutical industry, having held senior roles at multinational pharmaceutical conglomerate Johnson & Johnson (J&J) for over 40 years
- He most recently served as VP for Licensing & Acquisitions (Emerging Markets) at J&J Innovative Medicine (formerly Janssen Pharmaceuticals), a subsidiary of J&J, for 27 years
- In this role, he facilitated the deployment of external innovation ecosystems in emerging markets to access cutting-edge science and disruptive technologies supporting human health initiatives
- Mr Janssen collaborated with operating companies to negotiate and finalise multiple value-accretive deals, including in-licensing, acquisitions, co-promotions, distribution agreements, divestitures, and technology transfers
- His other roles within J&J included VP Business Development, as well as positions in R&D, international marketing sales and business development in J&J's consumer business, followed by pharmaceuticals
- During his tenure, Mr Janssen effectively executed multiple transactions that reinforced J&J's position as a strategic partner in addressing healthcare needs within emerging markets
- He has been recognised as a James E. Burke winner, J&J's most prestigious honour, awarded to executives that demonstrate outstanding leadership and integrity, while delivering exceptional business impact
- Mr Janssen is an existing shareholder of the Company and has been since its listing on the ASX
- His appointment adds important complementary skills, aligned with Tryp's TRP-8803 commercialisation objectives and pending clinical trials
- Mr Chris Ntoumenopoulos to transition to the role of Executive Director

Melbourne, Australia – Tryptamine Therapeutics Limited ('Tryp', 'TYP' or the 'Company') (ASX: TYP), a clinical-stage biotechnology company, is pleased to advise it has appointed Mr Herwig Janssen as Non-Executive Chairman, effective 12 May 2025. As part of this appointment, Mr Mark Davies will step down from his role as Chair, while Mr Chris Ntoumenopoulos will transition to the role of Executive Director. The Company is confident that these appointments strengthen the composition of the Board and leave it well positioned to oversee the next phase of its near-term clinical development pipeline and commercialisation strategy.

Mr Janssen is an internationally renowned healthcare and pharmaceutical executive. Most recently, he served as Vice President for Licensing & Acquisitions (Emerging Markets) at J&J Innovative Medicine (formerly Janssen Pharmaceuticals), a subsidiary of multinational conglomerate Johnson & Johnson for nearly three decades.

Mr Janssen brings more than 40 years of sector experience, where he has led business development activities for J&J across global emerging markets with a demonstrated track record in licensing, technology transfers and M&A. As a member of the Janssen family, he has a long association with J&J in connection with the strategic acquisition of Janssen Pharmaceuticals.



His other roles within the group include VP of Business Development in the US, which provided him with a strong understanding of J&J, while also demonstrating his ability to effectively execute a number of diverse deals and strategic agreements.

Following this, Mr Janssen undertook multiple senior positions in R&D, international marketing, sales and business development across J&J's consumer and pharmaceutical businesses. Mr Janssen's ability has been recognised through the James E Burke Award, which is the group's highest internal honour and is awarded for outstanding leadership and integrity, while delivering exceptional business impact.

Additional Board changes:

In addition to the appointment of Mr Janssen, the Company confirms that Mr Chris Ntoumenopoulos will transition to an Executive Director role, effective immediately. A Non-Executive Director since May 2024, the move to Executive Director is in line with Mr Ntoumenopoulos' intention to increase his operational and market engagement involvement as the Company embarks on the next phase of the comprehensive clinical development pathway for its lead drug candidate, TRP-8803, following the successful completion of Phase I trials.

Mr Ntoumenopoulos has a strong track record in the biotech sector, where he has advised on multiple transactions as managing director of boutique corporate advisory firm Twenty1 Corporate. His previous directorships include Race Oncology (ASX: RAC) and ResApp Health, which was acquired by Pfizer in 2022 for almost \$200m. He currently serves as Chairman of NeuroScientific Biopharmaceuticals Ltd and holds other directorships in the ASX biotech sector.

Concurrently, Mr Mark Davies will step down from his role as Chairman, effective from 12 May 2025. Mr Davies has a long association with Tryp, commencing with his investment in the IPO of Exopharm in 2018. As Chairman, he oversaw the strategic acquisition of Tryp Therapeutics in March 2024 and the subsequent renaming of the Company.

The Board would like to sincerely thank Mr Davies for his contribution and strategic vision in advancing the use of clinically-backed psilocin-assisted therapies and wish him well in future endeavours.

Management commentary:

Incoming Chairman, Mr Herwig Janssen said: *"I am pleased to be joining the Board of Tryptamine at this juncture, with the Company having already established itself as a pioneer in the field of precision psychedelic therapies. My decision to join as Chairman was informed in part by my belief in the potential of these treatments to achieve improved health outcomes, and through its clinical program to-date, Tryptamine has demonstrated its commitment to designing and executing a comprehensive trial framework in accordance with best-in-class quality control standards."*

"As we advance to the next phase of trials, I look forward to leveraging my experience in international healthcare markets to help guide the strategic direction of the business and, in the process, advancing the field of psychedelic-assisted medicine with our world-first research and clinical development program."

Chief Executive Officer, Jason Carroll, said: *"The addition of Herwig as Chairman is a significant appointment. With decades of experience as a senior global healthcare executive, we look forward to benefiting from his insights to help guide the Company's commercialisation strategy at Board level. Along with Chris's transition to the Executive Director role, these Board changes are consistent with Tryp's stated strategy to continually augment our Board and management team with best-in-class candidates who have the required skill sets to oversee the advancement of our clinical development pathway. In turn, the Company is now ultimately positioned at an important juncture, with the pending commencement of world-first clinical trials for the use of our lead drug candidate TRP-8803 to treat Binge Eating Disorder (BED)."*

"I'd also like to take this opportunity to thank Mark Davies for his significant contribution as Chairman. Having



overseen a strategic acquisition, a \$6m funding round and the successful completion of Phase I trials, Mark hands over the reins with the Company in a strong position to achieve our commercial objectives. We look forward to updating investors on our next round of key milestones as we embark on an exciting clinical development pathway in the coming months.”

Executive Director appointment terms:

Mr Ntoumenopoulos will be employed under an Employment Contract (the ‘contract’), with remuneration of \$125,000 per annum (exclusive of statutory superannuation). The contract will commence on 12 May 2025 and has no fixed term. The Company or the Executive Director may terminate the contract without cause by providing 1 weeks’ written notice if continuous service has been not more than 6 months, or 4 weeks’ written notice if continuous service has been for more than 6 months. Certain post-employment restraints are applicable for up to 6 months post-employment where enforceable.

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.trypterapeutics.com.

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@trypterapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Risks associated with Psilocin



All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.